gene knockdown

KRAS siRNA (Human)

MBS8214149

15 nmol

365 USD

siRNA

KRAS siRNA (Human)

[KRAS]

[KRAS2; RASK2; GTPase KRas; K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras]

[GTPase KRas isoform b; GTPase KRas; GTPase KRas; Kirsten rat sarcoma viral oncogene homolog; K-Ras 2; Ki-Ras; c-K-ras; c-Ki-ras]

[KRAS]

[KRAS; KRAS; NS; NS3; CFC2; KRAS1; KRAS2; RASK2; KI-RAS; C-K-RAS; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS2; RASK2]

RASK_HUMAN

Human

188

KRAS siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.

> 97%

Lyophilized powder

Shipped at 4 degree C. Store at -20 degree C for one year.

RNA Interference (RNAi)

Source: Synthetic

Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency. Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well). Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human KRAS gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.

siRNA to inhibit KRAS expression using RNA interference

15718761

NP_004976.2

NM_004985.4

P01116

21,425 Da

ARMS-mediated Activation Pathway (1269471); Activation Of RAS In B Cells Pathway (1269187); Acute Myeloid Leukemia Pathway (83117); Acute Myeloid Leukemia Pathway (529); Adaptive Immune System Pathway (1269171); Alcoholism Pathway (585563); Alcoholism Pathway (587116); Aldosterone-regulated Sodium Reabsorption Pathway (130626); Aldosterone-regulated Sodium Reabsorption Pathway (130590); Axon Guidance Pathway (83065)

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region. [provided by RefSeq, Jul 2008]

KRas: Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Interacts with PHLPP. Interacts (active GTP-bound form preferentially) with RGS14. Alternate between an inactive form bound to GDP and an active form bound to GTP. Activated by a guanine nucleotide-exchange factor (GEF) and inactivated by a GTPase- activating protein (GAP). Belongs to the small GTPase superfamily. Ras family. 2 isoforms of the human protein are produced by alternative splicing. Protein type: G protein, monomeric; Motility/polarity/chemotaxis; G protein; Oncoprotein; G protein, monomeric, Ras. Chromosomal Location of Human Ortholog: 12p12.1. Cellular Component: extrinsic to internal side of plasma membrane; focal adhesion; mitochondrion; membrane; cytoplasm; plasma membrane; cytosol; lipid raft. Molecular Function: protein binding; GDP binding; GTP binding; GMP binding; protein complex binding; LRR domain binding. Biological Process: regulation of long-term neuronal synaptic plasticity; axon guidance; activation of MAPKK activity; nerve growth factor receptor signaling pathway; response to glucocorticoid stimulus; activation of NF-kappaB transcription factor; positive regulation of MAP kinase activity; small GTPase mediated signal transduction; positive regulation of cell proliferation; visual learning; negative regulation of neuron apoptosis; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; positive regulation of nitric-oxide synthase activity; cytokine and chemokine mediated signaling pathway; MAPKKK cascade; response to mineralocorticoid stimulus; social behavior; regulation of synaptic transmission, GABAergic; positive regulation of Rac protein signal transduction; negative regulation of cell differentiation; Ras protein signal transduction; insulin receptor signaling pathway; striated muscle cell differentiation; innate immune response; positive regulation of protein amino acid phosphorylation; blood coagulation; vascular endothelial growth factor receptor signaling pathway; actin cytoskeleton organization and biogenesis; leukocyte migration. Disease: Bladder Cancer; Gastric Cancer, Hereditary Diffuse; Pancreatic Cancer; Noonan Syndrome 3; Leukemia, Acute Myeloid; Breast Cancer; Lung Cancer; Schimmelpenning-feuerstein-mims Syndrome; Cardiofaciocutaneous Syndrome 2

15 nmol

365 USD

30 nmol

515